PODD vs. ARWR

Last updated Apr 1, 2026

Compare and contrast key facts about Insulet Corporation (PODD) and Arrowhead Pharmaceuticals, Inc. (ARWR).

Performance

PODD vs. ARWR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Insulet Corporation (PODD) and Arrowhead Pharmaceuticals, Inc. (ARWR). The values are adjusted to include any dividend payments, if applicable.

PODD vs. ARWR - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
PODD Insulet Corporation	-26.18%	8.88%	20.32%	-26.30%	10.64%	4.08%	49.32%	115.83%	14.96%	83.12%
ARWR Arrowhead Pharmaceuticals, Inc.	-5.56%	253.14%	-38.56%	-24.56%	-38.82%	-13.59%	20.97%	410.71%	237.50%	137.42%

Fundamentals

Market Cap PODD : $14.83B ARWR : $8.82B
EPS PODD : $3.50 ARWR : $1.46
PE Ratio PODD : 60.00 ARWR : 42.93
PS Ratio PODD : 5.47 ARWR : 7.96
PB Ratio PODD : 9.79 ARWR : 15.52
Total Revenue (TTM) PODD : $2.71B ARWR : $1.09B
Gross Profit (TTM) PODD : $1.94B ARWR : $1.08B
EBITDA (TTM) PODD : $456.00M ARWR : $360.26M

Returns By Period

In the year-to-date period, PODD achieves a -26.18% return, which is significantly lower than ARWR's -5.56% return. Over the past 10 years, PODD has underperformed ARWR with an annualized return of 20.13%, while ARWR has yielded a comparatively higher 29.03% annualized return.

PODD

• 1D: 0.88%
• 1M: -14.91%
• YTD: -26.18%
• 6M: -32.03%
• 1Y: -20.09%
• 3Y*: -13.03%
• 5Y*: -4.55%
• 10Y*: 20.13%

ARWR

• 1D: 8.76%
• 1M: -0.90%
• YTD: -5.56%
• 6M: 81.79%
• 1Y: 392.15%
• 3Y*: 35.15%
• 5Y*: -1.34%
• 10Y*: 29.03%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

PODD vs. ARWR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PODD

PODD Risk / Return Rank: 21
PODD Sharpe Ratio Rank: 19
PODD Sortino Ratio Rank: 18
PODD Omega Ratio Rank: 19
PODD Calmar Ratio Rank: 28
PODD Martin Ratio Rank: 21

ARWR

ARWR Risk / Return Rank: 99
ARWR Sharpe Ratio Rank: 99
ARWR Sortino Ratio Rank: 98
ARWR Omega Ratio Rank: 97
ARWR Calmar Ratio Rank: 99
ARWR Martin Ratio Rank: 99

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PODD vs. ARWR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Insulet Corporation (PODD) and Arrowhead Pharmaceuticals, Inc. (ARWR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	PODD	ARWR	Difference
Sharpe ratio Return per unit of total volatility	-0.51	5.59	-6.11
Sortino ratio Return per unit of downside risk	-0.60	4.63	-5.22
Omega ratio Gain probability vs. loss probability	0.93	1.60	-0.67
Calmar ratio Return relative to maximum drawdown	-0.46	14.35	-14.81
Martin ratio Return relative to average drawdown	-1.14	39.33	-40.47
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

PODD vs. ARWR - Sharpe Ratio Comparison

The current PODD Sharpe Ratio is -0.51, which is lower than the ARWR Sharpe Ratio of 5.59. The chart below compares the historical Sharpe Ratios of PODD and ARWR, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	PODD	ARWR	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.51	5.59	-6.11
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.11	-0.02	-0.09
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.48	0.39	+0.09
Sharpe Ratio (All Time) Calculated using the full available price history	0.29	-0.01	+0.30

Correlation

The correlation between PODD and ARWR is 0.26, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

PODD vs. ARWR - Dividend Comparison

Neither PODD nor ARWR has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

PODD vs. ARWR - Drawdown Comparison

The maximum PODD drawdown since its inception was -90.28%, smaller than the maximum ARWR drawdown of -99.24%. Use the drawdown chart below to compare losses from any high point for PODD and ARWR.

Drawdown Indicators

	PODD	ARWR	Difference
Max Drawdown Largest peak-to-trough decline	-90.28%	-99.24%	+8.96%
Max Drawdown (1Y) Largest decline over 1 year	-41.04%	-24.64%	-16.40%
Max Drawdown (5Y) Largest decline over 5 years	-61.31%	-88.94%	+27.63%
Max Drawdown (10Y) Largest decline over 10 years	-61.31%	-88.96%	+27.65%
Current Drawdown Current decline from peak	-40.52%	-61.42%	+20.90%
Average Drawdown Average peak-to-trough decline	-24.64%	-81.40%	+56.76%
Ulcer Index Depth and duration of drawdowns from previous peaks	16.53%	8.99%	+7.54%

Volatility

PODD vs. ARWR - Volatility Comparison

The current volatility for Insulet Corporation (PODD) is 10.42%, while Arrowhead Pharmaceuticals, Inc. (ARWR) has a volatility of 16.63%. This indicates that PODD experiences smaller price fluctuations and is considered to be less risky than ARWR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	PODD	ARWR	Difference
Volatility (1M) Calculated over the trailing 1-month period	10.42%	16.63%	-6.21%
Volatility (6M) Calculated over the trailing 6-month period	24.33%	46.06%	-21.73%
Volatility (1Y) Calculated over the trailing 1-year period	39.49%	71.17%	-31.68%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	42.04%	64.68%	-22.64%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	42.20%	74.13%	-31.93%

Financials

PODD vs. ARWR - Profitability Comparison

The chart below illustrates the profitability comparison between Insulet Corporation and Arrowhead Pharmaceuticals, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

PODD - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Insulet Corporation reported a gross profit of 568.60M and revenue of 783.80M. Therefore, the gross margin over that period was 72.5%.

ARWR - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Arrowhead Pharmaceuticals, Inc. reported a gross profit of 264.03M and revenue of 264.03M. Therefore, the gross margin over that period was 100.0%.

PODD - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Insulet Corporation reported an operating income of 146.30M and revenue of 783.80M, resulting in an operating margin of 18.7%.

ARWR - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Arrowhead Pharmaceuticals, Inc. reported an operating income of 40.81M and revenue of 264.03M, resulting in an operating margin of 15.5%.

PODD - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Insulet Corporation reported a net income of 101.60M and revenue of 783.80M, resulting in a net margin of 13.0%.

ARWR - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Arrowhead Pharmaceuticals, Inc. reported a net income of 30.81M and revenue of 264.03M, resulting in a net margin of 11.7%.